2026 年至 2032 年品牌非專利市場（依藥品類別、用途、給藥途徑、通路及地區分類）

品牌非專利市場估值－2026-2032

全球控制醫療成本的趨勢日益增強，推動了品牌非專利市場的發展。隨著全球醫療成本的上升，政府、保險公司和醫療保健提供者擴大轉向品牌學名藥。隨著多種重磅藥物的專利到期，學名藥製造商將以低成本替代品進入市場，加劇競爭並降低價格，幫助市場在 2024 年成長至超過 2548.1 億美元，到 2032 年達到 4030.7 億美元。

此外，品牌學名藥擁有良好的安全性、有效性和合規性記錄，這增加了醫療保健專業人員和患者的信任，並加速了學名藥的廣泛採用。這些因素共同推動了品牌學名藥的市場佔有率不斷成長。品牌學名藥是一種滿足可負擔性和品質雙重目標的醫療保健服務系統，預計從 2026 年到 2032 年，其複合年成長率將達到約 5.90%。

品牌非專利市場定義/概述

品牌學名藥是使用公司品牌名稱供應的專利到期藥品，在成本效益和品牌可靠性之間實現了平衡。學名藥廣泛應用於心血管、糖尿病和呼吸系統護理等各個治療領域，為品牌藥提供了具有成本效益的替代品，同時保持了品牌藥的品質和功效。隨著對具有成本效益的醫療保健解決方案的需求不斷成長、新興市場醫療保健成本不斷上升以及藥品專利的不斷到期，為製藥公司擴大其品牌學名藥組合創造了新的機會，品牌學名藥的未來前景一片光明。

政府大力推廣學名藥的舉措是否會推動品牌學名藥市場的發展？

品牌非專利是以公司品牌名稱供應的專利到期藥品，在成本效益和品牌可靠性之間實現了平衡。學名藥廣泛應用於心血管、糖尿病和呼吸系統護理等各個治療領域，為品牌藥提供了具有成本效益的替代品，同時保持了品牌藥的品質和功效。品牌學名藥的前景一片光明。對具有成本效益的醫療保健解決方案的需求不斷增加、新興市場的醫療保健成本不斷上升以及藥品專利到期的不斷到期，為製藥公司擴大其品牌學名藥組合提供了新的機會。

印度等國家就是此類措施的明顯例子，政府推出了 PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) 等計畫。該計劃旨在透過名為 Janaushadhi Kendras 的專門零售店以合理的價格供應優質藥品。此類項目不僅提高了學名藥的可近性和可負擔性，而且還促進了品牌學名藥的市場滲透。政府可以透過讓更多人獲得品牌學名藥學名藥來增加其市場佔有率。

在美國，藥品價格競爭和專利期限恢復法案（即Hatch Waxman法案）的推出起到了關鍵作用。該法案為學名藥的核准建立了框架，並包含解決品牌藥和學名藥製造商之間的專利糾紛的條款。這大大降低了學名藥的市場准入門檻。這樣的法律規範對於創造學名藥能夠蓬勃發展的競爭性市場環境至關重要。這樣的法律規範有助於將創新需求與平價藥品需求結合起來，從而促進品牌非專利市場的興起。

此外，歐盟積極推動學名藥的使用。歐盟的藥品策略強調需要負擔得起且可用的藥品，並鼓勵使用學名藥來實現這一目標。例如，歐盟制定了法規，加快學名藥的核准流程，並促進其在國家醫療保健系統中的使用。這些規定不僅將鼓勵學名藥的擴張，還將使品牌學名藥獲得更大的市場佔有率。透過支持學名藥，政府間接支持了品牌學名藥學名藥，該產業受益於人們對學名藥的普遍接受度和信任度的提高。

政府不斷推出推廣學名藥的舉措，推動了品牌學名藥產業的發展。旨在降低醫療成本、改善藥品取得管道和創造良好法規環境的措施非常重要。這些活動不僅促進了學名藥的使用，而且為品牌學名藥創造了良好的市場環境，為品牌學名藥提供了成本更低但可靠的學名藥替代品。隨著各國政府繼續推動平價醫療，品牌非專利市場預計將大幅擴張。

不斷增加的監管障礙是否會阻礙品牌非專利市場的成長？

品牌非專利領域的擴張正面臨日益增加的監管障礙的挑戰。最大的監管障礙之一是將品牌非專利推向市場所需的複雜而漫長的核准過程。美國食品藥物管理局（FDA）、歐洲藥品管理局（EMA）以及其他國家衛生當局等監管機構對藥品的安全性、有效性和品質保證制定了嚴格的標準。滿足這些標準通常需要進行大量的實驗室測試、記錄並遵守良好生產規範 (GMP)，這可能會導致產品延遲並增加製造商的成本。這種延誤可能會妨礙品牌學名藥的及時供應並減少市場競爭。

此外，不同地區不同的法律規範也造成了進一步的複雜性。每個國家可能都有自己的標準和核准流程，彼此之間可能存在很大差異。例如，學名藥可能在某些地區快速核准，但在其他地區面臨嚴格審查和延誤。這種不一致迫使生產商必須遵循多個法律規範，這會耗費大量資源和時間。規模較小的組織尤其可能難以部署必要的資源來應對這些監管差異，這限制了它們在全球範圍內有效競爭的能力。

此外，監管變化和升級可能會導致市場波動和不可預測性。政府和監管機構定期更新其政策，以跟上新的健康問題、技術突破和製藥業的變化。雖然這些更新對於保護公眾健康和安全很重要，但合規要求也可能迅速變更。製造商必須透過重新評估生產方法、進行額外測試和更新文件來不斷適應這些變化。這些持續的調適要求可能會擾亂生產計劃、增加營運成本並阻礙品牌學名藥市場的擴張。

智慧財產權和專利訴訟是主要的監管障礙。品牌學名藥製造商經常面臨原產公司為保護其市場力量和智慧財產權而提出的法律挑戰。專利問題可能導致昂貴且漫長的訴訟，從而推遲品牌非專利的推出並增加製造商的法律費用。此外，授予新藥的監管獨佔權可能會在專利到期後繼續有效，為原創公司提供額外的市場保護，但會推遲品牌非專利的到來。處理這些複雜的法律和監管問題需要大量的法律經驗和財務資源，這對小型企業來說尤其沉重。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

第4章。按藥品類別分類的品牌非專利市場

• 抗高血壓藥
• 荷爾蒙
• 抗代謝藥

第5章 品牌非專利市場（按應用）

• 腫瘤學
• 心血管疾病

第6章 品牌非專利市場（依通路）

• 醫院藥房
• 零售藥局
• 網路藥局

第6章 依給藥途徑分類的品牌非專利市場

• 口服
• 局部的

第7章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第8章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第9章 競爭態勢

• 主要企業
• 市場佔有率分析

第10章 公司簡介

• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Sanofi
• Novartis AG
• Pfizer Inc.
• Endo International plc
• Mylan NV
• Fresenius SE & Co. KGaA

第11章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第12章 附錄

• 簡稱列表
• 來源和參考文獻

Branded Generics Market Valuation - 2026-2032

The increasing global trend of healthcare cost containment drive the branded generics market. As healthcare costs climb around the world, governments, insurers, and providers are increasingly turning to branded generics as a less expensive alternative to expensive branded pharmaceuticals. The patent expiration of several blockbuster pharmaceuticals has allowed generic manufacturers to enter the market with lower-cost alternatives, promoting competition and driving down prices propelling the market growth surpassing USD 254.81 Billion in 2024 and reaching USD 403.07 Billion by 2032.

Furthermore, the established track record of safety, efficacy, and regulatory compliance of branded generics is increasing trust among healthcare professionals and patients, hastening their uptake. These factors combined lead to the growing market share of branded generics, which meet the dual goals of affordability and quality in healthcare delivery systems globally growth is expected to grow at a CAGR of about 5.90% from 2026 to 2032.

Branded Generics Market: Definition/ Overview

Branded generics are off-patent pharmaceuticals supplied under a company's brand name, providing a balance of cost-effectiveness and brand dependability. They are widely utilized in a variety of therapeutic areas, including cardiovascular, diabetic, and respiratory therapies, and provide cost-effective alternatives to brand-name drugs while maintaining quality and efficacy. The future of branded generics looks promising, thanks to rising demand for cost-effective healthcare solutions, rising healthcare expenditure in emerging markets, and the ongoing expiration of drug patents, which creates new opportunities for pharmaceutical companies to expand their branded generics portfolios.

Will Rising Government Initiatives to Promote Generic Products is Driving the Branded Generics Market?

Branded generics are off-patent pharmaceuticals supplied under a company's brand name, providing a balance of cost-effectiveness and brand dependability. They are widely utilized in a variety of therapeutic areas, including cardiovascular, diabetic, and respiratory therapies, and provide cost-effective alternatives to brand-name drugs while maintaining quality and efficacy. The future of branded generics looks promising, thanks to rising demand for cost-effective healthcare solutions, rising healthcare expenditure in emerging markets, and the ongoing expiration of drug patents, which creates new opportunities for pharmaceutical companies to expand their branded generics portfolios.

Countries such as India provide a clear example of such measures, with the government launching schemes such as the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). This plan attempts to supply excellent medications at reasonable prices through dedicated retail stores called as Janaushadhi Kendras. Such programs not only increase the availability and affordability of generic drugs, but also promote branded generics' market penetration. Governments can help raise the market share of branded generics by making them more accessible to a bigger population.

In the United States, the introduction of the Drug Price Competition and Patent Term Restoration Act, sometimes known as the Hatch-Waxman Act, was critical. This Act established a framework for generic drug approval and included provisions to settle patent disputes between brand-name and generic manufacturers. It has greatly reduced the obstacles for generic medications to enter the market. Such regulatory frameworks are critical for creating a competitive market environment in which branded generics can flourish. They help to combine the demand for innovation with the need for cheap drug solutions, resulting in the rise of the branded generics market.

Furthermore, the European Union has actively promoted the use of generic medications. The EU's pharmaceutical strategy emphasizes the need of affordable and accessible medications, and it encourages the use of generics to accomplish this goal. For example, the EU has developed regulations to expedite the approval process for generic medications and promote their usage in national healthcare systems. These regulations not only promote the expansion of generic pharmaceuticals, but also allow branded generics to gain market share. Governments indirectly help the branded generics industry by supporting generics, which gain from improved acceptance and trust in generic medications in general.

Rising government measures to promote generic products are boosting the branded generics sector. Policies aiming at lowering healthcare costs, enhancing medicine access, and fostering a favorable regulatory environment are critical. These activities not only promote the use of generics, but also provide a favorable market climate for branded generics, which provide a low-cost yet dependable alternative to brand-name medications. As governments continue to promote affordable healthcare, the branded generics market is projected to expand significantly.

Will Rising Regulatory Barriers Hinder the Growth of the Branded Generics Market?

Rising regulatory obstacles provide a substantial challenge to the expansion of the branded generics sector. One of the biggest regulatory barriers is the complex and time-consuming approval processes required to bring branded generics to market. Regulatory entities such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities have strict criteria for pharmaceutical safety, efficacy, and quality assurance. Meeting these standards frequently necessitates considerable clinical testing, paperwork, and Good Manufacturing Practices (GMP) compliance, which can cause product delays and cost increases for manufacturers. These delays can impede the timely availability of branded generics, reducing their competitive edge in the market.

Furthermore, differences in regulatory frameworks among areas add an extra layer of complication. Each country may have its own set of criteria and approval processes that vary greatly from one another. For Instance, a branded generic may receive speedy approval in one region but face severe examination and delays in another. This inconsistency forces producers to traverse multiple regulatory frameworks, which can be resource-intensive and time-consuming. Smaller organizations, in particular, may struggle to deploy the resources required to manage these regulatory variances, thus limiting their capacity to compete effectively on a worldwide scale.

In addition, regulation changes and upgrades might lead to market instability and unpredictability. Governments and regulatory bodies routinely revise their policies to accommodate new health concerns, technological breakthroughs, and changes in the pharmaceutical industry. While these updates are critical for safeguarding public health and safety, they can also result in rapid changes in compliance requirements. Manufacturers must constantly adjust to these changes, which may include reevaluating their manufacturing methods, undertaking additional testing, and updating documentation. This ongoing requirement for adaption can interrupt manufacturing timelines and raise operating costs, impeding the expansion of the branded generics market.

Intellectual property rights and patent litigation create considerable regulatory impediments. Branded generics producers frequently face legal challenges from originator businesses looking to safeguard their market dominance and intellectual property. Patent issues can result in costly and extended litigation, delaying the release of branded generics and increasing manufacturers' legal fees. Furthermore, regulatory exclusivities given to new pharmaceuticals may last beyond patent expiration, offering further market protection to originator businesses while delaying the arrival of branded generics. Navigating these legal and regulatory intricacies necessitates significant legal experience and financial resources, which can be especially taxing for small and medium-sized businesses.

Category-Wise Acumens

Will Rising Demand for Anti-Hypertensive Drugs Boost the Branded Generics Market?

The increasing demand for antihypertensive medications is expected to greatly enhance the branded generics market. High blood pressure, sometimes known as hypertension, is a common chronic illness that affects millions of people worldwide. It is a major risk factor for cardiovascular disease, stroke, and other health consequences, thus proper care is critical. As hypertension awareness grows and healthcare systems work to reduce the burden of chronic diseases, there is a greater demand for low-cost treatment choices such as branded generics.

Branded generics provide a compelling value proposition by offering pharmaceuticals that are bioequivalent to their branded equivalents yet less expensive. This economic issue is essential in areas where healthcare budgets are limited or where individuals may pay a considerable amount of their prescription expenditures out of pocket. Branded generics are quality-assured alternatives to brand-name antihypertensive pharmaceuticals, allowing for more access to important prescriptions and increasing treatment adherence and outcomes.

Furthermore, the aging population, as well as the increasing prevalence of lifestyle-related risk factors such as obesity and sedentary lifestyles, contribute to the rise in hypertension. These demographic and lifestyle trends continue to drive up demand for antihypertensive drugs among a wide range of patient populations. Branded generics producers are reacting to this need by broadening their product portfolios to include a wide range of antihypertensive medications, increasing market penetration and satisfying the different needs of healthcare professionals and patients.

Furthermore, regulatory assistance and actions encouraging generic medications contribute to the expansion of the branded generics market for antihypertensive treatments. Governments and healthcare authorities throughout the world are increasingly recognizing the value of generics in lowering healthcare costs and enhancing access to important medicines. Policies that encourage generic substitution and speed approval processes for generic pharmaceuticals contribute to a competitive market in which branded generics can thrive. These regulatory frameworks provide an enabling climate for businesses to invest in the development and production of high-quality branded generic antihypertensive medicines.

The hormones area in the branded generics market is expanding rapidly due to a number of causes. Diabetes, thyroid diseases, and menopausal troubles are among the most common hormonal disorders worldwide. As knowledge and diagnostic capabilities improve, more people are being diagnosed with these illnesses, which increases demand for hormone replacement medicines and other treatments. Furthermore, advances in medical research and technology have resulted in the creation of novel and improved hormone therapies, accelerating market expansion. The aging population, combined with lifestyle changes and environmental variables, is driving up the demand for effective hormone therapy.

Will Increasing Demand for Oral Route Formulations Fuel the Branded Generics Market?

The increasing demand for oral route formulations is expected to drive significant growth in the branded generics industry. Oral drugs are the most prevalent and favored method of drug delivery due to its comfort, ease of administration, and familiarity with both healthcare providers and patients. This preference applies to a wide range of therapeutic areas, including chronic disorders like hypertension, diabetes, and cardiovascular problems, as well as acute infections that require pain relief or antibiotic therapy.

This desire stems from the increasing worldwide burden of chronic diseases. Long-term management of conditions such as hypertension and diabetes necessitates the use of trustworthy and cost-effective treatments. Branded generics provide a tempting alternative by offering pharmaceuticals that are bioequivalent to their brand-name equivalents yet less expensive. This affordability is critical in areas with low healthcare budgets or where patients pay a major amount of their prescription costs out of pocket, increasing access and adherence to treatment.

Additionally, advances in pharmaceutical formulation technology continue to spur innovation in oral drugs. These improvements improve drug delivery systems, increase bioavailability, and reduce dose frequency, resulting in better patient compliance and treatment outcomes. For example, extended-release formulations allow for less frequent administration, which improves patient comfort and may improve therapeutic efficacy. Pharmaceutical companies are investing in the development of novel oral formulations that suit specific patient needs, such as pediatric formulations or those designed for senior populations, hence increasing the market potential for branded generics.

Furthermore, governmental assistance and actions encouraging generic drugs play an important role in driving market growth. Governments and healthcare authorities around the world are progressively promoting the use of generics to decrease healthcare costs and enhance access to important medicines. Policies that simplify the approval process for generic pharmaceuticals and encourage generic substitution create an atmosphere in which branded generics producers can enter and compete in the market. These regulatory frameworks contribute to patients' access to safe, effective, and inexpensive oral pharmaceuticals, hence promoting worldwide branded generics market growth.

Topical administration is the second fastest-growing segment of the branded generics industry. Topical drugs are administered directly to the skin or mucous membranes, providing targeted treatment with less systemic side effects than oral medications. This approach is especially popular for dermatological disorders like eczema, psoriasis, and acne, because direct treatment to afflicted regions delivers specific therapeutic advantages. Topical formulations are also rapidly being used in pain treatment, wound care, and cosmetic dermatology, which is supporting their widespread adoption and market expansion.

Country/Region-wise

Will Rising Emphasis on Cost-Effective Treatments in North America Drive the Branded Generics Market?

In North America, the pharmaceutical environment is shifting significantly toward cost-effective therapies, which is projected to drive the expansion of the branded generics market. Branded generics are drugs that are bioequivalent to branded counterparts but are sold under a different trade name. This category has grown in popularity since it is less expensive than original branded pharmaceuticals, making it a more appealing option for healthcare providers, insurers, and patients.

The increase of branded generics in North America reflects the growing effort to keep healthcare prices low. With healthcare spending on the rise, both governments and private insurers are looking for ways to cut costs while maintaining treatment efficacy and safety. Branded generics provide a tempting alternative because they strike a compromise between affordability and quality, meeting regulatory standards while being more competitively priced than branded rivals.

Additionally, the patent expiration of some blockbuster pharmaceuticals has created chances for generic producers to enter the market with their own variants. The patent cliff phenomenon enables generic businesses to develop cost-effective replacements once the original pharmaceuticals' exclusive market rights expire. As a result, healthcare organizations are increasingly adopting these options to successfully control finances while ensuring patients' access to critical therapies.

Furthermore, the increasing acceptance of generic pharmaceuticals by healthcare professionals and patients fuels the growth of the branded generics industry. Generics have a long history of safety and efficacy, overcoming past concerns about their quality. This trust, combined with the economic benefits, drives stakeholders to adopt branded generics more quickly, resulting in market growth.

Will Increasing Demand for Affordable Healthcare in Asia-Pacific Propel the Branded Generics Market?

The growing desire for cheap healthcare in the Asia-Pacific region is a crucial factor driving the growth of the branded generics market. This region's economies are diverse, with varying healthcare infrastructures and access levels, but many countries share a critical need for cost-effective treatment choices. Branded generics provide an attractive answer by offering pharmaceuticals that are bioequivalent to their branded equivalents but less expensive, making them available to a larger market segment.

The sheer size of the population in Asia-Pacific drives the market for branded generics, as do the associated healthcare concerns. Countries such as India, China, Indonesia, and others suffer significant illness loads while providing diverse levels of healthcare access. Branded generics provide an opportunity to close affordability gaps, ensuring that vital medicines are accessible to a greater number of patients and enhancing overall healthcare outcomes.

Governments throughout the area are beginning to see the economic benefits of supporting generics. Policies and activities that promote the use of generics over branded pharmaceuticals help to lower healthcare costs and distribute resources more efficiently. This governmental support fosters an environment in which pharmaceutical companies can invest in and extend their branded generics portfolios, fulfilling the growing demand in these countries.

Furthermore, the recurring patent expirations of important branded pharmaceuticals provide opportunities for both domestic and multinational pharmaceutical businesses to launch branded generics. This competition promotes innovation while driving down prices, making healthcare more affordable and accessible. As a result, healthcare providers, insurers, and patients are more likely to prefer branded generics for their cost-effectiveness without sacrificing quality, which accelerates market growth.

Competitive Landscape

The competitive landscape of the branded generics market is characterized by the presence of numerous regional and local manufacturers who focus on producing cost-effective alternatives to branded drugs. These companies often operate in emerging markets, leveraging lower production costs and local market knowledge to gain a competitive edge. Additionally, contract manufacturing organizations (CMOs) play a significant role by providing production capabilities for pharmaceutical companies looking to enter the branded generics space without investing in extensive manufacturing infrastructure. The market is also marked by collaborations and partnerships between smaller firms and larger pharmaceutical companies, aiming to expand their product portfolios and market reach. Despite intense competition, opportunities remain abundant for new entrants due to the growing demand for affordable medication options globally.

Some of the prominent players operating in the branded generics market include:

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Reddy's Laboratories Ltd.

Lupin Limited

Sanofi

Novartis AG

Pfizer, Inc.

Endo International plc

Mylan N.V.

Fresenius SE & Co KGaA

Latest Developments

In May 2024, The FDA continues to receive a constant supply of Abbreviated New Drug Applications (ANDAs) for branded generic drugs. This trend is indicative of a growing branded generics market, driven by the expiration of brand-name drug patents and rising demand for more affordable medication options. The FDA approved several new branded generics, including Edaravone for amyotrophic lateral sclerosis, Emtricitabine and Tenofovir Alafenamide Fumarate for HIV treatment, and Imatinib for chronic myelogenous leukemia. These approvals are likely to improve patient access to these vital treatments while lowering healthcare expenditures.

In September 2023, Novartis, the Swiss pharmaceutical company, disclosed additional financial data for its generics and biosimilars subsidiary Sandoz today (5 September), ahead of a planned spin-off in early October. The proposal was disclosed in August of last year and follows similar measures by Pfizer, Johnson & Johnson, and GlaxoSmithKline.

In November 2023, Rajeev Raghuvanshi underlined the Indian pharmaceutical business must change its thinking and invest more in research and development. The DCGI also emphasized the importance of shifting the focus from volume to value in order to maintain its position as the 'pharmacy of the world.

Branded Generics Market, By Category

• Drug Class:
• Anti-hypertensive
• Hormones
• Antimetabolites
• Application:
• Oncology
• Cardiovascular Diseases
• Route of Administration:
• Oral
• Topical
• Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Branded Generics Market, By Drug Class

• Anti-hypertensive
• Hormones
• Antimetabolites

5. Branded Generics Market, By Application

• Oncology
• Cardiovascular Diseases

6. Branded Generics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

6. Branded Generics Market, By Route of Administration

• Oral
• Topical

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Sanofi
• Novartis AG
• Pfizer Inc.
• Endo International plc
• Mylan N.V.
• Fresenius SE & Co. KGaA

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References